2024-10-12 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**Company Overview:**  Johnson & Johnson is a multinational healthcare company that develops, manufactures, and sells pharmaceuticals, medical devices, and consumer healthcare products.

**Performance Analysis:**

**1. Relative Performance:**
* **Cumulative Return:** JNJ: 33.93%, VOO (S&P 500): 134.11%
* **Return Difference:** -100.18%
* **Relative Divergence:** 4.67% (This indicates that JNJ's performance is currently lagging behind VOO by a significant margin, sitting at the lower end of its historical performance range compared to VOO.)

**2. Recent Price Trend:**
* **Closing Price:** $160.48
* **5-day Moving Average:** $160.13
* **20-day Moving Average:** $162.57
* **60-day Moving Average:** $161.65
  
   The stock price is currently trading slightly below its 5-day, 20-day, and 60-day moving averages. This suggests a potential short-term downtrend.

**3. Technical Indicators:**
* **RSI:** 32.24 (This suggests that the stock is currently in oversold territory, which could indicate a potential rebound.)
* **PPO:** -0.23 (This indicates a negative momentum in the stock price, suggesting a potential for continued downward movement.)
* **Delta_Previous_Relative_Divergence:** -8.03  (This indicates a recent (20-day) decrease in relative divergence, suggesting a potential for further underperformance compared to VOO.)
* **Expected_Return:** 0.0% (This indicates no expected return over the next 5 years compared to VOO, considering current investment amount.)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |
| 2024-02-16 | 10.32 | 21.35 B$ |

* **Most Recent Earnings (2024-07-25):** The company reported EPS of $1.95, beating analysts' estimates of $1.87. Revenue of $22.45 billion also exceeded expectations, demonstrating strong performance and a healthy growth trajectory. 

**5. News and Recent Issues:**
* **Recent Market Outlook:** The market sentiment surrounding JNJ remains mixed. While some analysts remain optimistic about the company's long-term prospects, others are concerned about the ongoing litigation regarding its talcum powder products, which could impact its financial performance.
* **Analyst Opinions:**  Analyst recommendations for JNJ are currently mixed, with some suggesting a "Hold" rating and others suggesting a "Buy" rating.
* **Performance Highlights:**  Despite recent challenges, JNJ remains a well-established and profitable company with a strong track record. The company has continued to invest in research and development, launching new products and expanding into new markets.

**6. Summary:**

JNJ is currently lagging behind the S&P 500 in terms of performance. However, its recent earnings results have been positive, suggesting a potential for a rebound in the near future. While the company faces legal challenges, its long-term prospects remain strong. Technical indicators suggest a potential for continued downward momentum, but the stock is currently in oversold territory, which could lead to a bounce back.

**7. Recommendations:**

Investors should monitor JNJ's performance and the progress of the legal proceedings surrounding its talcum powder products closely. While the company has a strong track record and a solid financial position, the litigation and market sentiment present significant risks. Investors should consider their risk tolerance and investment goals before making any decisions.
